{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-006106","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.245141+00:00","generated_at":"2026-05-23T00:41:41.591683+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NextCure Q1 net loss narrows to $11.0M; LNCB74 ADC Phase 1 dosing cohort 3","bullets":["Cash $55.9M as of March 31, 2025, down from $68.6M; expected runway into H2 2026.","Net loss $11.0M vs $17.1M YoY; R&D expense $7.9M vs $11.4M YoY due to 2024 restructuring.","LNCB74 (B7-H4 ADC) Phase 1 cleared cohort 2, dosing cohort 3; backfill cohorts planned H2 2025.","Proof-of-concept data readout for LNCB74 planned in first half of 2026.","Preclinical NC181 (Alzheimer's) and NC605 (osteogenesis imperfecta) seeking partners; IND filings possible in 12-18 months if funded."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-006106","json":"https://secwatch.observer/filing/0001558370-25-006106.json","markdown":"https://secwatch.observer/filing/0001558370-25-006106.md","text":"https://secwatch.observer/filing/0001558370-25-006106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000155837025006106/0001558370-25-006106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000155837025006106/nxtc-20250501x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T00:41:41.591683+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}